Aurinia Pharmaceuticals establishes up to $30M at-the-market facility
Aurinia Pharmaceuticals announced that it has entered into an Open Market Sale Agreement with Jefferies LLC pursuant to which the company may from time to time sell, through at-the-market offerings with Jefferies acting as sales agent or directly to Jefferies acting as principal, such common shares in the capital of the company as would have an aggregate offering price of up to $30M. Aurinia has also filed a prospectus supplement with securities regulatory authorities in Canada in the provinces of British Columbia, Alberta and Ontario, and with the United States SEC, which supplements Aurinia's short form base shelf prospectus dated March 26, 2018, and Aurinia's shelf registration statement on Form F-10 dated March 26, 2018, declared effective on March 29, 2018. The listing of any shares sold pursuant to the ATM offering is subject to the approval of the Toronto Stock Exchange and NASDAQ. Jefferies, at Aurinia's discretion and instruction, will use its commercially reasonable efforts to sell the Common Shares at market prices from time to time. Sales in the ATM offering will only be conducted in the United States through NASDAQ or another exchange at market prices. No sales will be conducted in Canada or through the Toronto Stock Exchange.